Investing.com -- ImmunityBio (NASDAQ:IBRX) stock surged 17.1% Wednesday after the European Commission granted conditional ...
ImmunityBio (IBRX) stock gains as EU grants conditional approval for the company's bladder cancer drug, Anktiva. Read more ...
Stocktwits on MSN
How high can IBRX stock go now? Here’s what Wall Street thinks after Saudi nod for bladder cancer filing
D. Boral Capital reiterated a ‘Buy’ rating and a $24 price target, implying nearly 300% upside from the stock's last close. ・Saudi regulators encouraged a filing for a bladder cancer therapy and ...
ImmunityBio partner Accord Healthcare to deploy an 85-person sales force to drive ANKTIVA commercialization across 30 countries -- Dublin-based subsidiary to support ImmunityBio's distribution and ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Padcev, an antibody-drug conjugate Pfizer acquired in ...
Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results